Published in final edited form as:

Exp Biol Med (Maywood). 2008 May ; 233(5): 496–506. doi:10.3181/0708-MR-231.

Nuclear Receptors and Inflammatory Diseases

Kun Wang and Yu-Jui Yvonne Wan¹

Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160

Abstract

It is well known that the steroid hormone glucocorticoid and its nuclear receptor regulate the inflammatory process, a crucial component in the pathophysiological process related to human diseases that include atherosclerosis, obesity and type II diabetes, inflammatory bowel disease, Alzheimer's disease, multiple sclerosis, and liver tumors. Growing evidence demonstrates that orphan and adopted orphan nuclear receptors, such as peroxisome proliferator-activated receptors, liver $\times$ receptors, the farnesoid $\times$ receptor, NR4As, retinoid $\times$ receptors, and the pregnane $\times$ receptor, regulate the inflammatory and metabolic profiles in a ligand-dependent or -independent manner in human and animal models. This review summarizes the regulatory roles of these nuclear receptors in the inflammatory process and the underlying mechanisms.

Keywords

nuclear receptor; peroxisome proliferator-activated receptors; liver $\times$ receptors; farnesoid $\times$ receptor; NR4As; retinoid $\times$ receptors; steroid xenobiotic receptor/pregnane $\times$ receptor; inflammation; liver

Introduction

Nuclear receptors are a class of intracellular transcription factors activated by ligands. One of the unique characteristics of nuclear receptors is that they can directly interact with DNA and control transcription, distinguishing them from other classes of receptors. Consequently, nuclear receptors play key roles in reproduction, development, and homeostasis of organisms (1–4).

According to their ligand-binding and DNA-binding properties, nuclear receptors are classified into three families. The first is the classic and most extensively characterized group, steroid- and thyroid-hormone receptors (1). Among these hormone receptors, glucocorticoid receptor (GR) is a ubiquitous receptor that switches off multiple inflammatory genes encoding cytokines, adhesion molecules, and inflammatory receptors. The second class is the orphan nuclear receptors, which are structurally related to nuclear hormone receptors but lack known physiological ligands. In this group, nerve growth factor-

induced clone B (Nur77), nuclear receptor related-1 (Nurr1), and neuron-derived orphan receptor-1 (NOR1) are involved in the inflammatory process (5). The third class of nuclear receptors includes adopted orphan nuclear receptors, which function as heterodimers with retinoid $\times$ receptor (RXR). These orphan receptors are considered adopted, as studies show that they can bind physiological ligands and display physiological effects. Members of this group participating in the regulation of inflammatory process include receptors for fatty acids (peroxisome proliferator activated receptors [PPARs]: PPAR α , β/δ , and γ), oxysterols (liver $\times$ receptors [LXRs]: LXR α , and β), bile acids (farnesoid $\times$ receptor [FXR]), xenobiotics (steroid and xenobiotic receptor/pregnane $\times$ receptor [SXR/PXR] and constitutive androstane receptor [CAR]) (6).

Chronic inflammation is one of the key players in the common pathophysiological process related to atherosclerosis, obesity, and type II diabetes. A constellation of symptoms in early metabolic syndrome, such as weight gain, insulin resistance, hypertension, hypertriglyceridemia, and low levels of high-density lipoprotein, are closely related with the above diseases. Inflammation also contributes to other chronic inflammatory diseases, such as inflammatory bowel disease (IBD), Alzheimer's disease (AD), multiple sclerosis (MS), and arthritis. Many inflammatory cells are part of the overall group of immune cells that participate in chronic inflammation. Upon stimuli, these cells release multiple inflammatory mediators that interact with and activate structural cells at the site of inflammation. Although inflammatory cells and mediators differ among chronic inflammation-induced diseases, they are characterized by increased expressions of multiple inflammatory genes and proteins, some of which are common to all inflammatory diseases, with others more specific to a particular disease. In this review, we focus on the regulatory effects and the possible molecular mechanisms of class two (orphan) and class three (adopted orphan) nuclear receptors on the pathogenesis of chronic inflammatory diseases that include atherosclerosis, metabolic syndrome, IBD, AD, and MS (7–14).

PPARs

The PPAR family is comprised of three closely related isotypes (PPAR α , β/δ , and γ), which have been identified in various species and are structurally homologous. PPAR α and PPAR γ are found predominantly in liver and adipose tissue, respectively, and PPAR β/δ is ubiquitously expressed. PPARs can be activated by fatty acids, fatty acid derivatives, and synthetic compounds. PPARs heterodimerize with RXRs and bind to peroxisome proliferator response elements (PPREs) located in the promoter region of their target genes. Each member of the PPAR family plays a distinct role in lipid metabolism. PPAR α enhances fatty acid combustion in liver by inducing genes that encode enzymes involved in β -oxidation (15, 16). In contrast, PPAR γ serves as an essential regulator for adipocyte differentiation and lipid storage in mature adipocytes by increasing the expression of several essential genes in this pathway (16–18). PPAR β/δ participates in epidermal maturation and skin wound healing as well as in lipid metabolism (19, 20).

PPARs are expressed in macrophages, in T and B cells, and in endothelial cells that collectively participate in inflammation and immunity. Activated PPARs are most effective in reducing chronic inflammatory processes having less effect in acute inflammation. The

anti-inflammatory effects of PPARs have been reviewed recently (21–27). One of the molecular mechanisms by which PPARs exert anti-inflammatory effects is their physical interactions with transcription factors, such as nuclear factor- κ B (NF- κ B), signal transducers and activators of transcription (STATs), nuclear factor of activated T cells (NF-AT), CAAT-enhancer binding protein (C/EBP), and activator protein 1 (AP-1). These interactions inhibit the expression of the majority of pro-inflammatory cytokines, chemokines, and enzymes. The second mechanism by which PPARs exert anti-inflammatory effects is sequestration of the common co-activators or co-repressors for transcription factors. For instance, PPAR α and C/EBP β compete for the co-activator glucocorticoid receptor-interacting protein-1/transcriptional intermediary factor (GRIP-1/TIF) and repress inflammatory gene expression (21–27).

The first PPAR identified, PPAR α , is activated by natural lipophilic ligands, like fatty acids and their derivatives, certain leukotriene products, and synthetic ligands, such as fibrates. PPAR α regulates lipid metabolism and transport, fatty acid oxidation, and glucose homeostasis. In addition, PPAR α exerts anti-inflammatory effects. The anti-inflammatory effects by PPAR α are conducted through inhibiting the induction of pro-inflammatory cytokines, adhesion molecules, and extra-cellular matrix proteins or by stimulating the production of anti-inflammatory molecules. In general, PPAR α reduces the production of proinflammatory cytokines, limiting vascular inflammatory responses and atherosclerosis. Most evidence suggests that PPAR α -mediated pathways inhibit the initiation and progression of atherosclerosis, especially the atherosclerosis-associated inflammatory response. Activated PPAR α represses the early atherogenic gene vascular cell adhesion molecular1 (VCAM-1) expression (28, 29). This leads to a reduction of leukocyte adhesion to endothelial cells of the arterial vessel wall and an inhibition of subsequent trans-endothelial leukocyte migration. PPAR α activators fenofibrate or Wy14,643 inhibit tumor necrosis factor- α (TNF- α)-induced VCAM-1 gene expression and significantly reduce adhesion of U937 cells (human leukemic monocyte lymphoma cell line) to cultured human endothelial cells (ECs) (30). PPAR α activation also decreases expression of inflammatory cytokines, such as interferon- γ (IFN- γ), TNF α , and interleukin (IL)-2 by Th1 cells (31, 32). In addition, PPAR α inhibits the induction of cyclooxygenase-2 (COX-2) expression stimulated by IL-1 β in smooth muscle cells (SMCs) (33). Aside from modulating the initiation stage of atherosclerosis, PPAR α inhibits the formation of macrophage foam cells during later stages of atherosclerosis and reduces the production of additional inflammatory cytokines, growth factors, and matrix metalloproteinases (MMPs) and enzymes. These effects are produced through limiting low density lipoprotein (LDL) oxidation and its uptake and inducing reverse cholesterol transport, such as CLA-1/scavenger receptor class B type I (SR-BI) and ATP-binding cassette transporter A1 (ABCA1) (34, 35). Furthermore, PPAR α may increase the stability of the atherosclerotic plaque and may limit plaque thrombogenicity. Repression of MMP-9 (36, 37), tissue factor (TF) (38, 39), and plasminogen activator inhibitor-1 (PAI-1) (40, 41) by activation of PPAR α may also partly account for these effects. In addition, activated PPAR α binds to PPRES or interacts with Sp1 at the promoter region of tumor suppressor p16 (p16) gene and enhances p16 gene expression. The up-regulated p16 inhibits the G1/S transition in SMCs and, subsequently, the cell-cycle progression and proliferation of the cells (42). The anti-inflammatory effect of

PPAR α has not only been demonstrated in animal atherogenic, dermatitis, and paw edema models (33, 43–45) but also in human patients (46). The chemotactic mediators and adhesion molecules are essential for recruitment of monocytes/macrophages, T cells, or neutrophils into the inflamed tissues. PPAR α agonists reduce the production of chemotactic mediators and adhesion molecules, such as monocyte chemoattractant protein-1 (MCP-1) (47), and its receptor chemokine (C-C motif) receptor-2 (CCR-2), IL-8 (48), and intercellular adhesion molecule-1 (ICAM-1) (49). PPAR α activation also induces the expression of anti-inflammatory mediator IL-10 (50) and cytochrome P450 4A (CYP4A), which degrades inflammatory fatty acids and leukotriene B₄ (LB₄), a potent chemotactic factor for neutrophils (51–53). In addition, PPAR α triggers monocyte/macrophage apoptosis (54); this, too, contributes to its anti-inflammatory effects *in vivo*.

The ubiquitously expressed PPAR β/δ is the last identified member of the PPAR family (55). The highest PPAR β/δ levels are found in small intestine, colon, heart, adipose tissues, and brain. Although little is known about the role of PPAR β/δ in comparison with that of PPAR α and γ , PPAR β/δ participates in epidermal maturation (19, 20, 56, 57). Recent studies have identified PPAR β/δ as an important regulator of atherosclerosis, lipid, glucose, and energy homeostasis (58–61).

One role of PPAR β/δ that has been elucidated is its involvement in the development of atherosclerosis. PPAR β/δ acts as a molecular switch between pro-atherogenic and anti-atherogenic activities. When atherosclerosis-prone LDL receptor-null mice are transplanted with PPAR β/δ -deficient bone marrow followed by consumption of an atherogenic diet, lesions and serum cholesterol profiles are reduced in the recipient mice (62, 63). Moreover, PPAR β/δ -/- macrophages display reduced inflammatory markers, such as MCP-1, IL-1 β , and MMP-9, suggesting that PPAR β/δ is pro-atherogenic (63). On the other hand, synthetic PPAR β/δ ligands suppress inflammation in wild-type macrophages, which is consistent with the reduced inflammation found in PPAR β/δ -null cells. This discrepancy has been interpreted in the following manner: PPAR β/δ binds to transcriptional repressors, such as B cell CLL/lymphoma 6 (BCL-6), in the absence of agonists, and is unable to inhibit expression of inflammatory genes, such as MCP-1 expression, but, in the presence of the agonists, BCL-6 is released and represses MCP-1 expression. Hence, genetic deletion of PPAR β/δ or activation of PPAR β/δ by the agonists leads to the dissociation of BCL-6 from PPAR β/δ and, consequently, represses the expression of MCP-1, MCP-3, and IL-1 β genes. The culmination of this series of activities produces anti-inflammatory effects (63).

PPAR β/δ participates in fat metabolism and prevents obesity. The PPAR β/δ agonist GW501516 produces remarkable changes in fat metabolic profiles in obese monkeys (64). GW501516 stimulates fatty acid β -oxidation by 50% in 3T3-L1 pre-adipocytes over-expressed with VP16-PPAR β/δ . GW501516 also increases fatty acid metabolism and uncoupling in C2C12 skeletal muscle cells (58). In leptin-receptor deficient (db/db) obese mice, the PPAR β/δ -specific agonist L165041 induces high-density lipoprotein (HDL)-cholesterol levels without affecting blood glucose or triglyceride levels (65). Activation of PPAR β/δ in adipose can reverse the obesity phenotype of db/db obese mice. PPAR β/δ transgenic mice, generated by expressing VP16-PPAR β/δ in adipose tissue, have decreased

lipid content in both serum and adipose tissue. In addition, the PPAR β/δ transgenic mice are completely resistant to high-fat diet-induced obesity (66).

In vitro studies show that activation of PPAR β/δ by GW0742 inhibits lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS), myeloperoxidase (MPO) activity, and epithelial inflammation (67). PPAR β/δ ligand L165041 reduces TNF α -induced up-regulation of VCAM-1 and MCP-1 expression as well as NF- κ B translocation in EAhy 926 human endothelial cell line (30, 36). Additionally, carrageenan-induced paw edema is reduced by PPAR β/δ ligand L783483 in rodents (68, 69). PPAR β/δ and PPAR γ may play redundant roles in inflammatory regulation (67). PPAR β/δ and γ agonists exhibit a similar profile of promoter specificity for inhibition of LPS target genes. At a low concentration (1 μ M), inhibition of iNOS and IL-12 p40 gene expression is PPAR γ -dependent; at a high concentration (50 μ M), this expression pattern is PPAR β/δ -dependent (67).

PPAR β/δ also functions in skin homeostasis and keratinocyte differentiation under normal and inflammatory conditions. Expression of PPAR β/δ is undetectable in healthy rodent skin; however, immediately following injury, elevated PPAR β/δ expression is observed in keratinocytes at the edges of skin wounds. This elevation continues throughout the entire healing process. In parallel, the production of PPAR β/δ endogenous ligand is induced and activates the newly synthesized PPAR β/δ . The enhanced PPAR β/δ activity increases the resistance of keratinocytes to apoptotic signaling. In addition, more pronounced inflammatory skin responses are observed in PPAR β/δ deficient mice. Thus, the cytokine-induced PPAR β/δ expression is crucial for wound healing, and its anti-apoptotic role ensures sufficient viable keratinocytes for wound re-epithelialization (56, 57).

In 1993, PPAR γ was discovered in mammals. The expression of PPAR γ is detected in vascular tissues, including ECs and vascular smooth muscle cells (VSMCs), and in monocytes/macrophages. PPAR γ ligands have various impacts on the above cells with a net effect of proven anti-atherosclerosis. In a variety of atherosclerogenic mouse models and balloon injury models, PPAR γ ligands attenuate atherosclerotic lesion formation and intimal hyperplasia. Results of studies show that PPAR γ is up-regulated in differentiated macrophages and atherosclerosis lesions. These results also indicate that multiple PPAR γ agonists consistently repress inflammation and reduce atherosclerosis in mice (62, 70–73). Thiazolidinediones (TZDs), synthetic PPAR γ ligands, reverse the induction of CD36, a scavenger receptor, in obese and atherosclerotic mouse models. This finding suggests that PPAR γ agonists reduce CD36 expression, resulting in decreased uptake of modified lipoproteins and inhibition of atherosclerosis (74). Furthermore, TZDs-activated PPAR γ suppresses monocytes/macrophages with reduced expression of inflammatory cytokines, including adhesion molecules, TNF- α , IL-1 β , iNOS, and gelatinase B. In addition, PPAR γ induces LXRA and, therefore, stimulates ABCA1-dependent cholesterol efflux from macrophages (35, 74). This induction is important in contributing to the anti-atherogenic effects of PPAR γ ligands. In human studies, TZDs decrease circulating inflammatory markers, including TNF- α , MMP-9, MCP-1, matrix soluble CD40 ligand (sCD40L), C-reactive protein, and white blood cell count (75–77). These findings demonstrate that

PPAR γ inhibits macrophage activation and that synthetic PPAR γ ligands have anti-inflammatory and anti-atherogenic effects.

PPAR γ is highly expressed in the colon. The potential link between PPAR γ and intestinal diseases was first reported in 1998 (78–80). Regulation of colon inflammation by PPAR γ has been demonstrated in both experimental models of colitis as well as in ulcerative colitis patients. There is now emerging interest in the roles of PPAR γ in the regulation of gut homeostasis and chronic IBD (81, 82). PPAR γ expression in colon epithelial cells is associated with intestinal microorganisms. LPS, *Saccharomyces boulardii*, and *Helicobacter pylori* increase PPAR γ expression in colon epithelial cells (HT-29 and Caco-2) and gastric cells (KatoIII) (83–85). Extremely low levels of PPAR γ have been reported in mouse colon that has nonfunctional Toll-like receptor 4 (TLR4) (86). Thus, LPS recognition of TLR4 likely is involved in the enhancement of PPAR γ expression by microorganisms. These results indicate the pivotal role of bacteria in the regulation of PPAR γ expression in epithelial cells. This may account for the PPAR γ expression pattern observed in the colon compared with other parts of the digestive tract. Taken together, PPAR γ is highly expressed in the colon and is a key receptor in the regulation of intestinal inflammation induced by bacteria. Results from other studies also indicate a role of PPAR γ in tumor suppression, especially in colon cancer.

Alzheimer's disease is characterized by a major inflammatory component associated with amyloidosis and neurodegeneration (87). In the AD model, amyloid β peptide (A β) is formed by cleavage of APP (amyloid precursor protein) through β -secretase 1 (BACE1). PPAR γ agonists reduce inflammatory cytokine-induced A β production. Moreover, PPAR γ -dependent suppression of the BACE1 promoter accounts for inhibition of pro-inflammatory cytokine-induced gene expression by non-steroidal anti-inflammatory drugs (NSAIDs). *In vivo* data show that BACE1 transcription and expression are reduced in APP transgenic mice upon oral pioglitazone (a PPAR γ agonist) treatment (88, 89). Recent results show that PPAR γ activation increases the uptake and clearance of A β from medium in glia and neuron cell culture models through unknown mechanisms (90). In addition, PPAR γ activation suppresses the expression of iNOS and COX-2, inhibits nitric oxide production, and prevents neuronal and microglial cell death *in vitro* and *in vivo* (12, 91).

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system with the characterized pathological process of multiple areas of white matter inflammation, demyelination, and glial sclerosis. Proinflammatory cytokines have been recognized as crucial factors in the pathogenesis of MS (12, 92). PPAR γ ligands, troglitazone and pioglitazone, significantly decrease the mRNA levels of CCL5/RANTES (regulated on activation, normal T cell expressed and secreted) and CCL3/macrophage inflammatory protein-1 (MIP-1) in experimental allergic encephalitis (EAE), an established animal model for MS (93). The anti-inflammatory effects of PPAR γ agonists in EAE mice may be due to PPAR γ agonist-mediated down-regulation of adhesion molecule expression (94), an important factor for EAE development.

In animal stroke and ischemic models, robust inflammatory responses exacerbate tissue damage. Some PPAR γ agonists repress inflammatory responses, reduce infarct volumes,

and improve sensorimotor function (12, 95). Utilizing a middle cerebral artery occlusion (MCAO) model in the rat, neuroprotective effects, characterized by reduced infarct size and improved neurological scores, have been reported after the administration of the synthetic PPAR γ agonist L796449 (96, 97). Both types of PPAR γ agonists, TZDs and non-TZDs, exert neuronprotective effects on experimental stroke models. PPAR γ activators repress MCAO-induced iNOS and MMP-9 expression, induce the cytoprotective stress protein heme oxygenase-1 (HO-1) in brain, and, thus, exert neuroprotective effects. Other studies have also validated the neuroprotective effects of PPAR γ (98–100).

The majority of studies demonstrate an anti-inflammatory role for PPAR γ activation; however, no anti-inflammatory activity or pro-inflammatory response of PPAR γ activation has been reported. Furthermore, anti-inflammatory effects of PPAR γ ligands still remain in PPAR γ knockout mice, questioning the anti-inflammatory actions of PPAR γ . Nevertheless, anti-inflammatory effects do exist for all members of the PPAR family, which at least partly explains their anti-inflammatory activities. Clearly, PPAR-independent anti-inflammatory effects cannot be excluded.

LXRs

LXRs (α and β) are important transcriptional factors controlling lipid and glucose metabolism as well as the inflammatory response (21, 101). LXRs heterodimerize with RXRs and regulate gene expression by binding to LXREs (LXR responsive elements) of target genes. LXRs are activated by physiologic levels of cholesterol metabolites, including 25-hydroxycholesterol and 24, 25-epoxycholesterol (102–104). LXR α is highly expressed in the liver; lower levels of LXR α are found in macrophages, adrenal glands, the intestine, adipose tissue, the lung, and the kidney. In contrast, LXR β is ubiquitously expressed (103).

The mechanism of anti-inflammatory effects by LXR is poorly understood. Because LXR response motifs have not been identified in the proximal promoters of repressed genes, an indirect mechanism, such as competition for co-activators, is predicted (105).

Studies show that LXR agonists induce cholesterol efflux and reverse cholesterol transport, inhibit macrophage-derived inflammation, and suppress the proliferation of VSMCs. By regulating the expression of multiple genes involved in these pathways, LXR agonists prevent the development and progression of atherosclerosis (101, 106, 107). Activation of LXRs protects against lesion development and causes regression of established lesions. An approximately 50% reduction of lesion size has been observed in atherosclerosis-prone ApoE $^{-/-}$ and LDLR $^{-/-}$ mice upon LXR ligand treatment (108). LXR agonists also reduce the size of pre-existing lesions in LDLR $^{-/-}$ mice, and such reduction is dependent on macrophage LXR activity (109). Moreover, transplantation of bone marrow from LXR α , β $^{-/-}$ mice into ApoE $^{-/-}$ and LDLR $^{-/-}$ mice produces a macrophage-specific loss of LXRs resulting in a marked increase in lesion size and accelerated atherosclerosis (110).

Studies have demonstrated that activated LXRs regulate whole-body lipid homeostasis by decreasing intestinal cholesterol absorption and inducing cholesterol efflux. LXRs also regulate the conversion of cholesterol to bile acids and lipogenesis. In macrophages, LXR activators induce cholesterol efflux transporters ABCA1, ABCG1, and ABCG4. LXR α , β

double-knockout mice exhibit increased cholesterol accumulation in vascular macrophages on a normal chow diet. Genetic deletion of the individual LXRs alone does not display this phenotype (109). The functions of LXRs in inflammation have been recently reviewed (101, 106, 111, 112)

Considerable evidence indicates that LXRs reciprocally repress a set of inflammatory genes upon bacterial, LPS, TNF- α , or IL-1 β stimulation (105). LXR ligands GW3965 and T1317 repress inflammatory genes (iNOS, COX-2, IL-6, IL-1 β , MCP-1, MCP-3, MMP-9, TF, and osteopontin) in macrophages derived from wild-type and LXR α or β single knockout mice (105, 112–115); however, such repression is diminished in macrophages that are derived from LXR α and β double knockout mice, indicating that both isoforms possess anti-inflammatory activity.

The beneficial outcomes of anti-inflammatory effects by LXR activators also are observed in neurodegenerative diseases, like AD. Inflammatory processes and altered cholesterol metabolism are risk factors for AD. The LXR agonist GW3965 significantly attenuates LPS-induced iNOS mRNA, nitrate secretion, iNOS, and COX-2 protein in murine microglial BV2 cells. Furthermore, in primary mixed glial cultures, GW3965 accelerates the clearance of inflammatory fibrillar A β (fA β) by phagocytes. Consistent with these findings, genetic loss of LXR signaling in APP/PS1 transgenic mice results in increased senile plaque accumulation (116, 117).

Notably, members of both the LXR and PPAR subfamilies are expressed in macrophages and in other cell types that are involved in the metabolism of fat and cholesterol as well as in the regulation of inflammation. They can influence the development of inflammatory responses in a ligand-dependent manner. Their combined effects on peripheral metabolism, foam cell formation, and vascular wall inflammation have made LXR and PPAR major targets in the treatment of cardiovascular diseases, obesity, and diabetes.

FXR

FXR plays essential roles in maintaining bile acid, cholesterol, and glucose homeostasis. FXR is highly expressed in tissues exposed to high concentrations of bile acids, including the liver, intestine, and kidney. More recently, FXR has been detected in white adipose tissue, atherosclerotic lesions, and VSMCs. The hydrophobic bile acid chenodeoxycholic acid (CDCA) is the most effective activator of FXR. Ligand-activated FXR binds to FXR response elements (FXREs) either as a heterodimer or as a monomer (118–120).

Recent studies indicate that FXR influences endothelial function and atherosclerosis; thus, FXR plays a regulatory role in the cardiovascular diseases and in metabolic syndrome (121). Guo and other researchers demonstrated that disruption of the FXR gene could attenuate atherosclerosis development, most likely resulting from reduced oxLDL-C uptake by macrophages (122, 123).

Hepatic inflammation can be observed in the hydrophobic bile acid-induced cholestasis rodent model (124) or after feeding a bile acid-supplemented diet (125). The proinflammatory effects of bile acids are proposed to act as FXR ligands and to induce

ICAM-1. Additionally, bile acid-activated kinase pathways, including protein kinase C, extracellular signal-regulated kinase (ERK), and JNK, contribute to hepatic inflammation (126–128). In hepatocytes, bile acid induces ICAM-1 expression through an FXRE located within the promoter region (125). In primary human endothelial cells, bile acid levels at a high concentration (100 μ M) induce ICAM-1, VCAM-1, and E-selectin expression through stimulation of NF- κ B and p38 MAPK signaling pathways. Moreover, bile acid-induced ICAM-1 and VCAM-1 proteins are sufficient to enhance the adhesion of human acute monocytic leukemia (THP-1) cells to human umbilical vein endothelial cells. This would suggest a potential pathological role of bile acids in the vasculature under conditions in which serum bile acid levels become elevated (129).

Inflammation is known to promote liver tumorigenesis (130–132). An intriguing link between FXR and hepatocarcinogenesis has been identified. FXR knockout mice display prominent liver injury and inflammation from 9 to 12 months of age. When the FXR knockout mice are 15 months old, hepatocellular adenoma and carcinoma, but not other tumor types, are developed spontaneously with an elevated expression of inflammatory genes (INF- γ , TNF- α , and IL-6). In contrast, no liver tumors are observed in wild-type mice of the same age (133). Diet enriched with bile acid strongly promotes N-nitrosodiethylamine-initiated liver tumorigenesis, whereas lowering the bile acid pool in FXR knockout mice significantly reduces the malignant lesions. These results suggest that the increased expression of pro-inflammatory genes in aging FXR knockout mice may eventually contribute to liver carcinogenesis (133).

NR4As

The NR4A subfamily includes three members: Nur77, Nurr1, and NOR1. Nur77 was documented first as an early response gene in nerve growth factor-stimulated rat pheochromocytoma cell line PC12 cells (134). Subsequently, Nurr1 and NOR1 were identified (135, 136). Nur77, Nurr1, and NOR1 are expressed in a wide variety of tissues, such as skeletal muscle, adipose, the heart, the kidney, T cells, the liver, and the brain. No classical ligands have been identified for Nur77, Nurr1, or NOR1. All three proteins can bind to NGFI-B response element (NBRE) as monomers (137) and with the palindromic Nur77 responsive element (NurRE) as homodimers and/or heterodimers (138, 139). Additionally, Nur77 and Nurr1 can heterodimerize with RXRs and mediate retinoid responses (140). NR4As are induced by multiple signaling molecules, such as hormones, growth factors, apoptotic stimuli, and inflammatory stimuli to regulate differentiation, proliferation, apoptosis, and survival of various cell types. The functional involvement of NR4As in regulating chronic inflammatory diseases like atherosclerosis has been investigated only recently (5).

NR4As are induced upon atherogenic stimuli to inhibit human foam cell formation and pro-inflammatory cytokine production. Over-expression of NR4As in human THP-1 macrophages results in down-regulation of IL-1 β , IL-6, IL-8, monocyte chemoattractant-1, MIP-1 α , and MIP-1 β . Moreover, ox-LDL is reduced by overexpression of NR4As (141). Knockdown of Nur77 or NOR-1 augments inflammatory responses and increases lipid loading. It has been demonstrated that NR4As reduce monocyte-to-macrophage

differentiation thus limiting human macrophage foam cell formation and inflammatory responses (141). Moreover, Nur77 interacts with p65 inhibiting IL-2 and IL-8 promoter activity, which suggests that NR4As transrepress the NF- κ B signaling pathway (142).

Crosstalk Between Nuclear Receptors and Cytokine Signaling Pathways During Inflammatory Processes

The crosstalk between nuclear receptors and other transcriptional factors regulates cytokine production or cytokine-mediated signaling transduction and cell responses. Several crosstalk mechanisms, including interactions between nuclear receptors and other transcriptional factors and modifications of nuclear receptors by kinases, have been demonstrated. For instance, GR and AP-1 physically interact on the target gene promoter containing the binding site for either of the two transcription factors. Thus, the interaction between GR and AP-1 prevents their binding to either the GR response element (GRE) site or the AP-1 site and antagonizes both regulators' activities. Most frequently, this crosstalk results in negative interference of both factors' transcriptional capacities if AP-1 is composed of c-jun/c-fos dimer. Such crosstalk is also observed in PPAR γ , sex steroids receptors, and vitamin D receptor (143, 144).

The expression and activity of nuclear receptors can be regulated by post-translational modifications, including phosphorylation, ubiquitylation, sumolation, and acetylation. Kinases associated with general transcription factors or ones that are activated in response to various signals (MAPK, Akt, PKA, and PKC) participate in this crosstalk. Such crosstalk often facilitates the recruitment of co-activators or components of the transcription machinery and, therefore, cooperates with the ligand to enhance transcriptional activation (143). For example, phosphorylation can alter all major domains of nuclear receptors and affect protein stability, nuclear localization, DNA binding, and protein-protein interactions, thereby affecting the overall transcriptional activity of the nuclear receptors.

Recent reports have investigated the link between inflammation-mediated cell signaling and regulation of nuclear receptors in the liver. Studies show that LPS signaling induces the rapid and significant reduction of the hepatic RXR α protein, but not of mRNA levels, and the redistribution of hepatic RXR α from nucleus to cytoplasm. It has been revealed that the LPS-induced release of IL-1 β from kupffer cells activates the JNK pathway, which phosphorylates RXR α at the Ser260 site, leading to further modification of RXR α (145). The alteration of RXR α triggers the rapid export of the receptor from nucleus to cytoplasm and the consequent degradation of the receptor and, therefore, the marked suppression of RXR α -targeted inflammatory gene expression (146). Crosstalk occurs between human PXR (hPXR)/RXR and NF- κ B signaling pathways as well. LPS or TNF- α activated NF- κ B represses SXR/RXR α -mediated gene expression through the direct interactions between the DNA binding domain of RXR α and p65. This interaction may prevent RXR α from binding to its consensus DNA sequences thus inhibiting PXR/RXR α -mediated transactivation (147). Moreover, reciprocal inhibition between NF- κ B and hPXR has been reported (6, 148). Activated PXR inhibits the activity of NF- κ B and its target genes (IL-1 α , IL-1 β , IL-6, IL-15, COX-2, ICAM-1) in the liver and the intestine. In addition, the small bowel of PXR $^{-/-}$ mice exhibits a prominent and increased chronic inflammatory infiltration. On the other

hand, NF- κ B activation reciprocally inhibits PXR and its target genes, whereas inhibition of NF- κ B enhances PXR activity. These findings clearly demonstrate the interaction between nuclear receptor PXR and NF- κ B.

Conclusions

Current understanding of the nuclear receptor-mediated regulation of chronic inflammatory processes and diseases has increased. Moreover, inflammatory cytokines crucial in governing a specific disease state may be sensitive or resistant to a particular nuclear receptor ligand. Clarification of the sensitivity of sets of inflammatory genes to particular nuclear receptor ligands will help design treatment options for specific inflammatory diseases. The presence of crosstalk between nuclear receptors and other transcriptional factors is also recognized. However, fully understanding the mechanisms of nuclear receptor action in a well-defined model is still necessary. Increased understanding in these areas will potentially assist in designing novel prevention and treatment options for specific chronic inflammatory diseases.

Acknowledgments

We thank Dr. Grace L. Guo and Ms. Barbara Brede for their comments and proofreading the manuscript.

Financial support was received from NIH grants CA53596, AA14147, and COBRE Molecular Biology Core, P20 RR021940.

References

1. Evans RM. The steroid and thyroid hormone receptor superfamily. *Science*. 1988; 240:889–895. [PubMed: 3283939]
2. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. *Science*. 2001; 294:1866–1870. [PubMed: 11729302]
3. Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? *Cell*. 1995; 83:859–869. [PubMed: 8521510]
4. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. *Cell*. 1995; 83:835–839. [PubMed: 8521507]
5. Bonta PI, Pols TW, de Vries CJ. NR4A nuclear receptors in atherosclerosis and vein-graft disease. *Trends in Cardiovasc Med*. 2007; 17:105–111. [PubMed: 17418373]
6. Pascucci JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, Maurel P. The Tangle of Nuclear Receptors that Controls Xenobiotic Metabolism and Transport: Crosstalk and Consequences. *Annu Rev Pharmacol Toxicol*. 2007
7. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *Journal of Clin Invest*. 2005; 115:1111–1119.
8. Walsh NC, Crotti TN, Goldring SR, Gravalles EM. Rheumatic diseases: the effects of inflammation on bone. *Immunol Rev*. 2005; 208:228–251. [PubMed: 16313352]
9. Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. *Gastroenterology Clin North Am*. 2006; 35:757–773.
10. Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, Dassopoulos T, Schumm P, Gregory FJ, Griffiths AM, Hanauer SB, Hanson J, Harris ML, Kane SV, Orkwis HK, Lahaie R, Oliva-Hemker M, Pare P, Wild GE, Rioux JD, Yang H, Duerr RH, Cho JH, Steinhart AH, Brant SR, Silverberg MS. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. *American J Gastroenterol*. 2006; 101:1012–1023.

11. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. *Inflamm Bowel Dis*. 2006; 12(Suppl 1):S3–S9. [PubMed: 16378007]
12. Heneka MT, Landreth GE. PPARs in the brain. *Biochim Biophys Acta*. 2007
13. Kalinin S, Gavriluk V, Polak PE, Vasser R, Zhao J, Heneka MT, Feinstein DL. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. *Neurobiol Aging*. 2007; 28:1206–1214. [PubMed: 16837104]
14. Knowles JW, Maeda N. Genetic modifiers of atherosclerosis in mice. *Arterioscler Thromb Vasc Biol*. 2000; 20:2336–2345. [PubMed: 11073835]
15. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. *Ann Rev Nutr*. 2001; 21:193–230. [PubMed: 11375435]
16. Berger J, Moller DE. The mechanisms of action of PPARs. *Ann Rev Med*. 2002; 53:409–435. [PubMed: 11818483]
17. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. *J Biol Chem*. 2001; 276:37731–37734. [PubMed: 11459852]
18. Tsai YS, Maeda N. PPARgamma: a critical determinant of body fat distribution in humans and mice. *Trends Cardiovasc Med*. 2005; 15:81–85. [PubMed: 16039966]
19. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, Metzger D, Chambon P, Duboule D, Wahli W. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. *J Cell Biol*. 2001; 154:799–814. [PubMed: 11514592]
20. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, Fluhmann B, Desvergne B, Wahli W. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. *Genes Dev*. 2001; 15:3263–3277. [PubMed: 11751632]
21. Castrillo A, Tontonoz P. PPARs in atherosclerosis: the clot thickens. *J Clin Invest*. 2004; 114:1538–1540. [PubMed: 15578084]
22. Valledor AF, Ricote M. Nuclear receptor signaling in macrophages. *Biochem Pharmacol*. 2004; 67:201–212. [PubMed: 14698033]
23. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. *Nat Rev*. 2002; 2:748–759.
24. Genolet R, Wahli W, Michalik L. PPARs as drug targets to modulate inflammatory responses? *Curr Drug Targets*. 2004; 3:361–375.
25. Rizzo G, Fiorucci S. PPARs and other nuclear receptors in inflammation. *Curr Opin Pharmacol*. 2006; 6:421–427. [PubMed: 16777482]
26. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. *Circulation*. 2007; 115:518–533. [PubMed: 17261671]
27. Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? *Fundam Clin Pharmacol*. 2006; 20:429–447. [PubMed: 16968414]
28. Nakai K, Itoh C, Kawazoe K, Miura Y, Sotoyanagi H, Hotta K, Itoh T, Kamata J, Hiramori K. Concentration of soluble vascular cell adhesion molecule-1 (VCAM-1) correlated with expression of VCAM-1 mRNA in the human atherosclerotic aorta. *Coron Art Dis*. 1995; 6:497–502.
29. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. *J Clin Invest*. 2001; 107:1255–1262. [PubMed: 11375415]
30. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, Junquero D, Colpaert FC, Delhon A. PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. *Eur J Pharmacol*. 2002; 435:143–151. [PubMed: 11821020]
31. Jones DC, Ding X, Daynes RA. Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. *J Biol Chem*. 2002; 277:6838–6845. [PubMed: 11726654]

32. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. *Circ Res.* 2002; 90:703–710. [PubMed: 11934839]
33. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. *Nature.* 1998; 393:790–793. [PubMed: 9655393]
34. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart JC, Tedgui A, Najib-Fruchart J, Staels B. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. *Circulation.* 2000; 101:2411–2417. [PubMed: 10821819]
35. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. *Nat Med.* 2001; 7:53–58. [PubMed: 11135616]
36. Shu H, Wong B, Zhou G, Li Y, Berger J, Woods JW, Wright SD, Cai TQ. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. *Biochem Biophys Res Commun.* 2000; 267:345–349. [PubMed: 10623622]
37. Eberhardt W, Akool el S, Rebhan J, Frank S, Beck KF, Franzen R, Hamada FM, Pfeilschifter J. Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor alpha agonists is indirect and due to a NO-mediated reduction of mRNA stability. *J Biol Chem.* 2002; 277:33518–33528. [PubMed: 12093797]
38. Marx N, Mackman N, Schonbeck U, Yilmaz N, Hombach V, Libby P, Plutzky J. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. *Circulation.* 2001; 103:213–219. [PubMed: 11208679]
39. Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. *Circulation.* 2001; 103:207–212. [PubMed: 11208678]
40. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. *Inflamm Res.* 2000; 49:497–505. [PubMed: 11089900]
41. Banfi C, Auwerx J, Poma F, Tremoli E, Mussoni L. Induction of plasminogen activator inhibitor 1 by the PPARalpha ligand, Wy-14,643, is dependent on ERK1/2 signaling pathway. *Thromb Haemost.* 2003; 90:611–619. [PubMed: 14515181]
42. Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart JC, Torpier G, Staels B. PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. *J Clin Invest.* 2005; 115:3228–3238. [PubMed: 16239970]
43. Sheu MY, Fowler AJ, Kao J, Schmuth M, Schoonjans K, Auwerx J, Fluhr JW, Man MQ, Elias PM, Feingold KR. Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. *J Invest Dermatol.* 2002; 118:94–101. [PubMed: 11851881]
44. Kippenberger S, Loitsch SM, Grundmann-Kollmann M, Simon S, Dang TA, Hardt-Weinelt K, Kaufmann R, Bernd A. Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation. *J Invest Dermatol.* 2001; 117:1430–1436. [PubMed: 11886504]
45. Taylor BK, Dadia N, Yang CB, Krishnan S, Badr M. Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. *Inflammation.* 2002; 26:121–127. [PubMed: 12083418]
46. Ye P, Li JJ, Su G, Zhang C. Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia. *Clin Chim Acta.* 2005; 356:229–232. [PubMed: 15936324]
47. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, Hama S, Borromeo C, Evans RM, Berliner JA, Nagy L. Role for peroxisome proliferator-activated receptor alpha in

- oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. *Circ Res*. 2000; 87:516–521. [PubMed: 10988245]
48. Ryoo S, Won M, Kim DU, Kim L, Han G, Park SK, Mukaida N, Maeng P, Yoo HS, Hoe KL. PPARalpha activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cells. *Biochem Biophys Res Commun*. 2004; 318:329–334. [PubMed: 15120605]
 49. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. *Arterioscler Thromb Vasc Biol*. 1999; 19:2094–2104. [PubMed: 10479650]
 50. Maruyama S, Kato K, Kodama M, Hirono S, Fuse K, Nakagawa O, Nakazawa M, Miida T, Yamamoto T, Watanabe K, Aizawa Y. Fenofibrate, a peroxisome proliferator-activated receptor alpha activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats. *J Atheroscler Thromb*. 2002; 9:87–92. [PubMed: 12236317]
 51. Jedlitschky G, Huber M, Volkl A, Muller M, Leier I, Muller J, Lehmann WD, Fahimi HD, Keppler D. Peroxisomal degradation of leukotrienes by beta-oxidation from the omega-end. *J Biol Chem*. 1991; 266:24763–24772. [PubMed: 1761571]
 52. Kikuta Y, Kusunose E, Endo K, Yamamoto S, Sogawa K, Fujii-Kuriyama Y, Kusunose M. A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloning and expression of leukotriene B4 omega-hydroxylase. *J Biol Chem*. 1993; 268:9376–9380. [PubMed: 8486631]
 53. Le Bouquin R, Lugnier A, Frossard N, Pons F. Expression of cytochrome P450 4A mRNA in mouse lung: effect of clofibrate and interleukin-1beta. *Fundam Clin Pharmacol*. 2004; 18:181–186. [PubMed: 15066132]
 54. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. *J Biol Chem*. 1998; 273:25573–25580. [PubMed: 9748221]
 55. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. *Proc Natl Acad Sci U S A*. 1994; 91:7355–7359. [PubMed: 8041794]
 56. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. *Proc Natl Acad Sci U S A*. 2002; 99:303–308. [PubMed: 11756685]
 57. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). *Mol Cell Biol*. 2000; 20:5119–5128. [PubMed: 10866668]
 58. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. *Cell*. 2003; 113:159–170. [PubMed: 12705865]
 59. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. *Nat Med*. 2004; 10:355–361. [PubMed: 15057233]
 60. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM. PPARdelta regulates glucose metabolism and insulin sensitivity. *Proc Natl Acad Sci U S A*. 2006; 103:3444–3449. [PubMed: 16492734]
 61. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. *J Clin Invest*. 2006; 116:590–597. [PubMed: 16511591]
 62. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Villedor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. *J Clin Invest*. 2004; 114:1564–1576. [PubMed: 15578089]

63. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. *Science*. 2003; 302:453–457. [PubMed: 12970571]
64. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. *Proc Natl Acad Sci U S A*. 2001; 98:5306–5311. [PubMed: 11309497]
65. Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, Cullinan CA, Sparrow CP, Baffic J, Berger GD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J. Activation of PPARdelta alters lipid metabolism in db/db mice. *FEBS Lett*. 2000; 473:333–336. [PubMed: 10818235]
66. Akiyama TE, Lambert G, Nicol CJ, Matsusue K, Peters JM, Brewer HB Jr, Gonzalez FJ. Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet. *J Biol Chem*. 2004; 279:20874–20881. [PubMed: 15001574]
67. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. *Proc Natl Acad Sci U S A*. 2003; 100:6712–6717. [PubMed: 12740443]
68. Wan YJ, Badr MZ. Inhibition of Carrageenan-Induced Cutaneous Inflammation by PPAR Agonists Is Dependent on Hepatocyte-Specific Retinoid X Receptor Alpha. *PPAR Res*. 2006; 2006:96341. [PubMed: 17259670]
69. Youssef J, Badr M. Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control. *J Biomed Biotechnol*. 2004; 2004:156–166. [PubMed: 15292582]
70. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. *J Clin Invest*. 2000; 106:523–531. [PubMed: 10953027]
71. Han KH, Chang MK, Boullier A, Green SR, Li A, Glass CK, Quehenberger O. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. *J Clin Invest*. 2000; 106:793–802. [PubMed: 10995790]
72. Hsueh WA. PPAR-gamma effects on the vasculature. *J Investig Med*. 2001; 49:127–129.
73. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. *Diab Care*. 2001; 24:392–397.
74. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, Tall AR. Increased CD36 protein as a response to defective insulin signaling in macrophages. *J Clin Invest*. 2004; 113:764–773. [PubMed: 14991075]
75. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. *Nature*. 1998; 391:82–86. [PubMed: 9422509]
76. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman BM, Freeman MW. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. *Nat Med*. 2001; 7:41–47. [PubMed: 11135614]
77. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature*. 1998; 391:79–82. [PubMed: 9422508]
78. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. *Nat Med*. 1998; 4:1053–1057. [PubMed: 9734399]
79. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. *Nat Med*. 1998; 4:1058–1061. [PubMed: 9734400]
80. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. *Nat Med*. 1998; 4:1046–1052. [PubMed: 9734398]

81. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P. PPARgamma as a new therapeutic target in inflammatory bowel diseases. *Gut*. 2006; 55:1341–1349. [PubMed: 16905700]
82. Rousseaux C, Desreumaux P. The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPAR-gamma and IBD). *J Soc Biol*. 2006; 200:121–131. [PubMed: 17151549]
83. Konturek PC, Kania J, Kukharsky V, Raithel M, Ocker M, Rembiaz K, Hahn EG, Konturek SJ. Implication of peroxisome proliferator-activated receptor gamma and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection. *J Pharmacol Sci*. 2004; 96:134–143. [PubMed: 15492468]
84. Lee SK, Kim HJ, Chi SG, Jang JY, Nam KD, Kim NH, Joo KR, Dong SH, Kim BH, Chang YW, Lee JI, Chang R. Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells. *Korean J Gastroenterol*. 2005; 45:328–334. [PubMed: 15908765]
85. Li H, Han DW, Zhang SM, Zhao LF. The effect of intestinal endotoxemia on the balance of Th1/Th2 in patients with hepatitis B. *Chinese J Hepatol*. 2005; 13:939–940.
86. Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, Desreumaux P. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. *Gastroenterology*. 2003; 124:1265–1276. [PubMed: 12730867]
87. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. *Neurobiol Aging*. 2000; 21:383–421. [PubMed: 10858586]
88. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. *J Neurosci*. 2003; 23:9796–9804. [PubMed: 14586007]
89. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, Heneka MT. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. *Proc Natl Acad Sci U S A*. 2006; 103:443–448. [PubMed: 16407166]
90. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. *J Neurosci*. 2004; 24:10908–10917. [PubMed: 15574741]
91. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. *J Neurosci*. 2000; 20:558–567. [PubMed: 10632585]
92. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. *Ann Rev Immunol*. 1992; 10:153–187.
93. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. *Ann Neurol*. 2002; 51:694–702. [PubMed: 12112074]
94. Wang N, Verna L, Chen NG, Chen J, Li H, Forman BM, Stemerman MB. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. *J Biol Chem*. 2002; 277:34176–34181. [PubMed: 12107164]
95. Zheng Z, Yenari MA. Post-ischemic inflammation: molecular mechanisms and therapeutic implications. *Neurol Res*. 2004; 26:884–892. [PubMed: 15727272]
96. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. *Neuroscience*. 2005; 130:685–696. [PubMed: 15590152]

97. Victor NA, Wanderi EW, Gamboa J, Zhao X, Aronowski J, Deiningner K, Lust WD, Landreth GE, Sundararajan S. Altered PPARgamma expression and activation after transient focal ischemia in rats. *Eur J Neurosci.* 2006; 24:1653–1663. [PubMed: 17004929]
98. Allahtavakoli M, Shabanzadeh AP, Sadr SS, Parviz M, Djahanguiri B. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke. *Clin Exp Pharmacol Physiol.* 2006; 33:1052–1058. [PubMed: 17042914]
99. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Diansani C, Danni O, Thiemermann C, Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. *Eur J Pharmacol.* 2006; 530:70–80. [PubMed: 16386242]
100. Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. *J Neurochem.* 2006; 97:435–448. [PubMed: 16539667]
101. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. *J Clin Invest.* 2006; 116:607–614. [PubMed: 16511593]
102. Peet DJ, Janowski BA, Mangelsdorf DJ. The LXRs: a new class of oxysterol receptors. *Curr Opin Genet Dev.* 1998; 8:571–575. [PubMed: 9794827]
103. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. *Ann Rev Cell Dev Biol.* 2000; 16:459–481. [PubMed: 11031244]
104. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Willson TM. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. *J Biol Chem.* 1997; 272:3137–3140. [PubMed: 9013544]
105. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. *Nat Med.* 2003; 9:213–219. [PubMed: 12524534]
106. Barish GD, Evans RM. PPARs and LXRs: atherosclerosis goes nuclear. *Trends in endocrinology and metabolism: Trends Endocrinol Metab.* 2004; 15:158–165.
107. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. *Cell.* 1998; 93:693–704. [PubMed: 9630215]
108. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J, Tippin TK, Wang X, Lusis AJ, Hsueh WA, Law RE, Collins JL, Willson TM, Tontonoz P. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. *Proc Natl Acad Sci U S A.* 2002; 99:7604–7609. [PubMed: 12032330]
109. Levin N, Bischoff ED, Daige CL, Thomas D, Vu CT, Heyman RA, Tangirala RK, Schulman IG. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. *Arterioscler Thromb Vasc Biol.* 2005; 25:135–142. [PubMed: 15539622]
110. Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, Daige CL, Thomas D, Heyman RA, Mangelsdorf DJ, Wang X, Lusis AJ, Tontonoz P, Schulman IG. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. *Proc Natl Acad Sci U S A.* 2002; 99:11896–11901. [PubMed: 12193651]
111. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. *Mol Endocrinol.* 2003; 17:985–993. [PubMed: 12690094]
112. Chinetti G, Fruchart JC, Staels B. Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR. *Biochem Soc Trans.* 2006; 34:1128–1131. [PubMed: 17073767]
113. Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ, Tontonoz P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. *J Biol Chem.* 2003; 278:10443–10449. [PubMed: 12531895]
114. Mardanov PV, Krasnov AN, Kurshakova M, Nabirochkina EN, Georgieva SG. Study of the novel tissue-specific RNA polymerase II transcription factor. *Genetika.* 2005; 41:536–541. [PubMed: 15909913]

115. Ogawa D, Stone JF, Takata Y, Blaschke F, Chu VH, Towler DA, Law RE, Hsueh WA, Bruemmer D. Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. *Circ Res*. 2005; 96:e59–e67. [PubMed: 15790955]
116. Cao G, Bales KR, DeMattos RB, Paul SM. Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. *Curr Alzheimer Res*. 2007; 4:179–184. [PubMed: 17430244]
117. Carter CJ. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. *Neurochem Int*. 2007; 50:12–38. [PubMed: 16973241]
118. Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. *Trends Mol Med*. 2007; 13:298–309. [PubMed: 17588816]
119. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. *Cell*. 1995; 81:687–693. [PubMed: 7774010]
120. Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. *J Biol Chem*. 2003; 278:104–110. [PubMed: 12393883]
121. Cariou B, Staels B. FXR: a promising target for the metabolic syndrome? *Trends Pharmacol Sci*. 2007; 28:236–243. [PubMed: 17412431]
122. Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer B Jr, Gonzalez FJ. Effects of FXR in foam-cell formation and atherosclerosis development. *Biochim Biophys Acta*. 2006; 1761:1401–1409. [PubMed: 17110163]
123. Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ, Edwards PA. FXR deficiency causes reduced atherosclerosis in *Ldlr*^{-/-} mice. *Arterioscler Thromb Vasc Biol*. 2006; 26:2316–2321. [PubMed: 16825595]
124. Li MK, Crawford JM. The pathology of cholestasis. *Semin Liver Dis*. 2004; 24:21–42. [PubMed: 15085484]
125. Qin P, Borges-Marcucci LA, Evans MJ, Harnish DC. Bile acid signaling through FXR induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes. *Am J Physiol Gastrointest Liver Physiol*. 2005; 289:G267–G273. [PubMed: 15817812]
126. Gupta S, Stravitz RT, Dent P, Hylemon PB. Down-regulation of cholesterol 7 α -hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. *J Biol Chem*. 2001; 276:15816–15822. [PubMed: 11278771]
127. Qiao D, Chen W, Stratagoules ED, Martinez JD. Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signaling. *J Biol Chem*. 2000; 275:15090–15098. [PubMed: 10748108]
128. Stravitz RT, Rao YP, Vlahcevic ZR, Gurley EC, Jarvis WD, Hylemon PB. Hepatocellular protein kinase C activation by bile acids: implications for regulation of cholesterol 7 α -hydroxylase. *Am J Physiol*. 1996; 271:G293–G303. [PubMed: 8770045]
129. Qin P, Tang X, Elloso MM, Harnish DC. Bile acids induce adhesion molecule expression in endothelial cells through activation of reactive oxygen species, NF- κ B, and p38. *Am J Physiol Heart Circ Physiol*. 2006; 291:H741–H747. [PubMed: 16582018]
130. Balkwill F, Coussens LM. Cancer: an inflammatory link. *Nature*. 2004; 431:405–406. [PubMed: 15385993]
131. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKK β links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell*. 2004; 118:285–296. [PubMed: 15294155]
132. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF- κ B functions as a tumour promoter in inflammation-associated cancer. *Nature*. 2004; 431:461–466. [PubMed: 15329734]
133. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. *Cancer Res*. 2007; 67:863–867. [PubMed: 17283114]

134. Nakai A, Kartha S, Sakurai A, Toback FG, DeGroot LJ. A human early response gene homologous to murine nur77 and rat NGFI-B, and related to the nuclear receptor superfamily. *Mol Endocrinol.* 1990; 4:1438–1443. [PubMed: 2283997]
135. Law SW, Conneely OM, DeMayo FJ, O'Malley BW. Identification of a new brain-specific transcription factor, NURR1. *Mol Endocrinol.* 1992; 6:2129–2135. [PubMed: 1491694]
136. Ohkura N, Hijikuro M, Yamamoto A, Miki K. Molecular cloning of a novel thyroid/steroid receptor superfamily gene from cultured rat neuronal cells. *Biochem Biophys Res Commun.* 1994; 205:1959–1965. [PubMed: 7811288]
137. Wilson TE, Fahrner TJ, Johnston M, Milbrandt J. Identification of the DNA binding site for NGFI-B by genetic selection in yeast. *Science.* 1991; 252:1296–1300. [PubMed: 1925541]
138. Paulsen RE, Weaver CA, Fahrner TJ, Milbrandt J. Domains regulating transcriptional activity of the inducible orphan receptor NGFI-B. *J Biol Chem.* 1992; 267:16491–16496. [PubMed: 1644831]
139. Philips A, Lesage S, Gingras R, Maira MH, Gauthier Y, Hugo P, Drouin J. Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. *Mol Cell Biol.* 1997; 17:5946–5951. [PubMed: 9315652]
140. Perlmann T, Jansson L. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. *Genes Devel.* 1995; 9:769–782. [PubMed: 7705655]
141. Bonta PI, van Tiel CM, Vos M, Pols TW, van Thienen JV, Ferreira V, Arkenbout EK, Seppen J, Spek CA, van der Poll T, Pannekoek H, de Vries CJ. Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. *Arterioscler Thromb Vasc Biol.* 2006; 26:2288–2294. [PubMed: 16873729]
142. Hong CY, Park JH, Ahn RS, Im SY, Choi HS, Soh J, Mellon SH, Lee K. Molecular mechanism of suppression of testicular steroidogenesis by proinflammatory cytokine tumor necrosis factor alpha. *Mol Cell Biol.* 2004; 24:2593–2604. [PubMed: 15024051]
143. Wang L, Zhang X, Farrar WL, Yang X. Transcriptional crosstalk between nuclear receptors and cytokine signal transduction pathways in immunity. *Cell Mol Immunol.* 2004; 1:416–424. [PubMed: 16293210]
144. Herrlich P. Cross-talk between glucocorticoid receptor and AP-1. *Oncogene.* 2001; 20:2465–2475. [PubMed: 11402341]
145. Adam-Stitah S, Penna L, Chambon P, Rochette-Egly C. Hyper-phosphorylation of the retinoid X receptor alpha by activated c-Jun NH2-terminal kinases. *J Biol Chem.* 1999; 274:18932–18941. [PubMed: 10383391]
146. Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation. *Nucl Recept.* 2004; 2:4. [PubMed: 15312234]
147. Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, Gallo MA, Xie W, Tian Y. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. *J Biol Chem.* 2006; 281:17882–17889. [PubMed: 16608838]
148. Zhou C, Tabb MM, Nelson EL, Grun F, Verma S, Sadatrafiei A, Lin M, Mallick S, Forman BM, Thummel KE, Blumberg B. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. *J Clin Invest.* 2006; 116:2280–2289. [PubMed: 16841097]